Why Indivior Pharmaceuticals Stock Topped the Market Today

Indivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals on November 2, 2026, creating a leading CNS biopharmaceutical company. The combined entity will operate under the Supernus name and ticker, with Indivior shareholders receiving a $1 billion special cash dividend and owning approximately 56.5% of the merged company. The merger aims to achieve $125 million in annual cost synergies.